Aligos Therapeutics, Inc. ( (ALGS) ) has released its Q3 earnings. Here is a breakdown of the information Aligos Therapeutics, Inc. presented to its investors.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing best-in-class therapies for liver and viral diseases, using its scientific expertise to address metabolic dysfunction-associated steatohepatitis and viral infections like hepatitis B and coronaviruses.
In its third quarter of 2024, Aligos Therapeutics reported significant business progress, highlighted by the positive topline HERALD data in MASH subjects, demonstrating ALG-055009’s potential in reducing liver fat. The company is also advancing its clinical programs for hepatitis B and COVID-19 treatments.
The key financial metrics for the quarter include a net loss of $19.3 million, which represents a slight increase compared to the same period last year. Research and development expenses rose to $16.8 million, primarily due to third-party clinical trial costs, while general and administrative expenses decreased to $4.6 million. The company’s cash position stands at $74.9 million, with confidence in funding operations through the end of 2025.
Strategically, Aligos is progressing with its drug candidates, including ALG-000184 for CHB and ALG-097558 for COVID-19, exploring potential partnerships and collaborations to support these developments. The company is also involved in new studies with partners like Xiamen Amoytop Biotech and the NIAID.
Looking ahead, Aligos Therapeutics is focused on completing Phase 2 studies and further advancing its clinical programs, positioning itself for potential successes in 2025 and beyond, as it seeks to make impactful contributions to the treatment of liver and viral diseases.
